Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20905351 | 0.87 | MAOB (0.58) | MAOBNR4A2CYP4F2CYP4A11FFAR1 | |
| SCHEMBL3976490 | 0.87 | MAOB (0.55) | MAOBNR4A2CYP4F2CYP4A11FFAR1 | |
| SCHEMBL5326113 | 0.85 | PPARG (0.59) | MAOBNR4A2CYP4F2CYP4A11FFAR1 | |
| SCHEMBL5533396 | 0.84 | PPARA (0.49) | FFAR1TSHRRAB9A | |
| SCHEMBL12802274 | 0.83 | CYP1A2 (0.54) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL278432 | 0.83 | MAOB (0.62) | MAOBNR4A2CYP4F2CYP4A11BCHE | |
| SCHEMBL9434980 | 0.81 | MAOB (0.59) | MAOBNR4A2CYP4F2CYP4A11FFAR1 | |
| SCHEMBL14740848 | 0.81 | CYP1A2 (0.45) | SMN1; SMN2KDM4EALDH1A1MEN1GAA | |
| SCHEMBL6036145 | 0.79 | PKM (0.60) | MAOBNR4A2CYP4F2CYP4A11SMPD1 | |
| SCHEMBL29368049 | 0.79 | CYP1A2 (0.44) | SMN1; SMN2KDM4EALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2019075259-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | CORNELL UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
| US-7560586-B2 | Acid and ester compounds and methods of using the same | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060041164-A1 | Acid and ester compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2006-02-23 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| EP-1487776-A4 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORP (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1487776-A1 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082802-A1 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | MAOB 1987/4885NR4A2 1584/4885CYP4F2 3856/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | MAOB 3322/4885NR4A2 102/4885CYP4F2 255/4885 |
| US-20060041164-A1 | Acid and ester compounds and methods of using the same | NR1H3, NR1H2, PPARA | MAOB 3129/4885NR4A2 161/4885CYP4F2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.